Contains fulltext : 137979.pdf (publisher's version ) (Open Access)OBJECTIVE: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to develop the first evidence-based detection algorithm for PAH in SSc. METHODS: In this cross-sectional, international study conducted in 62 experienced centres from North America, Europe and Asia, adults with SSc at increased risk of PAH (SSc for >3 years and predicted pulmonary diffusing capacity for carbon monoxide <60%) underwent a broad panel of non-invasive assessments followed by diagnostic right heart catheterisation (RHC). Univariable and multivariable analyses s...
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in sy...
Objective: Early detection of pulmonary arterial hypertension (PAH) is crucial to improve patient ou...
There is evidence that early screening for pulmonary arterial hypertension (PAH) in systemic scleros...
Objective: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
OBJECTIVE: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
Background: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosi...
Abstract Background Pulmonary arterial hypertension (PAH) is one of the most relevant causes of deat...
National audienceINTRODUCTION: Pulmonary arterial hypertension (PAH) is a severe complication of sys...
National audienceINTRODUCTION: Pulmonary arterial hypertension (PAH) is a severe complication of sys...
Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclero...
Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclero...
Pulmonary arterial hypertension (PAH) carries a high morbidity and mortality burden in Systemic Scle...
Systemic sclerosis (SSc) is a rare disease, with unfavorable clinical course and prognosis, characte...
Background: Systemic sclerosis (scleroderma, SSc) is a chronic multisystem autoimmune disease charac...
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in sy...
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in sy...
Objective: Early detection of pulmonary arterial hypertension (PAH) is crucial to improve patient ou...
There is evidence that early screening for pulmonary arterial hypertension (PAH) in systemic scleros...
Objective: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
OBJECTIVE: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
Background: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosi...
Abstract Background Pulmonary arterial hypertension (PAH) is one of the most relevant causes of deat...
National audienceINTRODUCTION: Pulmonary arterial hypertension (PAH) is a severe complication of sys...
National audienceINTRODUCTION: Pulmonary arterial hypertension (PAH) is a severe complication of sys...
Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclero...
Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclero...
Pulmonary arterial hypertension (PAH) carries a high morbidity and mortality burden in Systemic Scle...
Systemic sclerosis (SSc) is a rare disease, with unfavorable clinical course and prognosis, characte...
Background: Systemic sclerosis (scleroderma, SSc) is a chronic multisystem autoimmune disease charac...
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in sy...
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in sy...
Objective: Early detection of pulmonary arterial hypertension (PAH) is crucial to improve patient ou...
There is evidence that early screening for pulmonary arterial hypertension (PAH) in systemic scleros...